GSK plc (GSK) Fair Value & Analysis
Healthcare · US · Market cap $102B
GSK plc
GSK · US
Fair value as of: Jul 16, 2026
From 25 valuation models · updated yesterday
Share price +1.1% over the past month.
Price vs Fair Value (12 months)
12‑month range $34.89 – $60.14 · fair‑value band $32.62 – $78.44 · the $52.77 price screens below the $52.94 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
GSK plc (GSK) currently trades at $52.77, while our model-based Fair Value estimate is $52.94, implying the stock looks roughly 0.3% fairly valued today. We read business quality at 74/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, GSK plc generated revenue of $32.8B at a net margin of 17.8%. Revenue grew 1.5% year over year. It earns a return on equity of 40.9%. Net debt stands at $14.3B. Fundamentals as of Jul 16, 2026
Our scenario range runs from $32.62 (bear case) to $78.44 (bull case); at $52.77, the current price sits within that range. The share trades about 13% below its 52-week high and 54% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -36% fair-value upside, at 0%, GSK screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
GSK plc reported revenue of $32.7B in FY2025 versus $24.7B in FY2021, a compound +7.2%/yr. Reported net income was $5.7B in FY2025, compounding +6.9%/yr from FY2021.
Is GSK fairly valued? → Check now
Recent news
- GSK's Jemperli hits goal in phase 2 trial for rectal cancer
- UBS keeps GSK at 'neutral' with focus on chief executive's strategy update
- GSK: Hansoh Pharma's Ris-Rez Shows Survival Benefit In Lung Cancer Trial
- Ionis extends losses as Roche scraps two partnered studies
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,136 | $630.79 | -44% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| AbbVie Inc 4AB | €196.25 | €89.57 | -54% |
| Roche Holding 1RO | €377.80 | €280.03 | -26% |
| Merck & Co MRCK34 | R$76.74 | R$50.09 | -35% |
| Novartis AG NVSN | 2,601 MXN | 2,706 MXN | +4% |
| AstraZeneca PLC ZEG | €160.70 | €86.60 | -46% |
| Novo Nordisk A/S NOV | €39.18 | €38.90 | -1% |
| Amgen Inc AMGN | $345.60 | $219.60 | -36% |
| Gilead Sciences, Inc GILD34 | R$320.43 | R$51.59 | -84% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is GSK plc (GSK) undervalued?
What is the fair value of GSK?
What is the quality score of GSK?
What is the revenue of GSK plc (GSK)?
What is the net profit margin of GSK?
Does GSK plc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full GSK plc analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.